In January 2025, IQVIA and NVIDIA announced a strategic collaboration aimed at creating custom foundation models and AI workflows to accelerate research and clinical development in the life sciences.

On June 11, 2025, IQVIA unveiled new artificial intelligence agents designed to enhance workflows and accelerate insights in the healthcare sector during the GTC Paris event.

These AI agents, powered by NVIDIA technology, represent a significant advancement in agentic AI tailored specifically for life sciences, transforming business processes and improving patient outcomes.

Utilizing NVIDIA's NIM Agent Blueprints for rapid development, the NeMo Customizer for fine-tuning, and NeMo Guardrails to ensure safe deployment, these agents are set to enhance operational efficiency.

IQVIA remains committed to responsible AI use, ensuring privacy, regulatory compliance, and patient safety while leveraging advanced analytics and healthcare data.

The applications of these AI agents include target identification, clinical data review, literature review, market assessment, and healthcare professional engagement.

Kimberly Powell, vice president of healthcare at NVIDIA, emphasized that these AI agents will significantly improve efficiency in clinical trial planning, assisting researchers with tasks such as literature reviews.

Bhavik Patel, president of IQVIA Commercial Solutions, highlighted the collaboration with NVIDIA as a crucial opportunity to deliver the efficient workflows demanded by the modern life sciences industry.

Looking ahead, the upcoming IQVIA TechIQ 2025 conference in September will further explore the future of life sciences and feature insights from industry leaders, including NVIDIA.